Does Motor Symptoms Asymmetry Predict Motor Outcome of Subthalamic Deep Brain Stimulation in Parkinson's Disease Patients?

Parkinson's disease deep brain stimulation motor asymmetry motor outcome predictors subthalamic nucleus

Journal

Frontiers in human neuroscience
ISSN: 1662-5161
Titre abrégé: Front Hum Neurosci
Pays: Switzerland
ID NLM: 101477954

Informations de publication

Date de publication:
2022
Historique:
received: 29 04 2022
accepted: 23 05 2022
entrez: 8 7 2022
pubmed: 9 7 2022
medline: 9 7 2022
Statut: epublish

Résumé

In Parkinson's disease (PD), the side of motor symptoms onset may influence disease progression, with a faster motor symptom progression in patients with left side lateralization. Moreover, worse neuropsychological outcomes after subthalamic nucleus deep brain stimulation (STN-DBS) have been described in patients with predominantly left-sided motor symptoms. The objective of this study was to evaluate if the body side of motor symptoms onset may predict motor outcome of bilateral STN-DBS. This retrospective study included all consecutive PD patients treated with bilateral STN-DBS at Grenoble University Hospital from 1993 to 2015. Demographic, clinical and neuroimaging data were collected before (baseline condition) and 1 year after surgery (follow-up condition). The predictive factors of motor outcome at one-year follow-up, measured by the percentage change in the MDS-UPDRS-III score, were evaluated through univariate and multivariate linear regression analysis. A total of 233 patients were included with one-year follow-up after surgery [143 males (61.40%); 121 (51.90 %) right body onset; 112 (48.10%) left body onset; mean age at surgery, 55.31 ± 8.44 years; mean disease duration, 11.61 ± 3.87]. Multivariate linear regression analysis showed that the left side of motor symptoms onset did not predict motor outcome (β = 0.093, 95% CI = -1.967 to 11.497, p = 0.164). In this retrospective study, the body side of motor symptoms onset did not significantly influence the one-year motor outcome in a large cohort of PD patients treated with bilateral STN-DBS.

Sections du résumé

Background UNASSIGNED
In Parkinson's disease (PD), the side of motor symptoms onset may influence disease progression, with a faster motor symptom progression in patients with left side lateralization. Moreover, worse neuropsychological outcomes after subthalamic nucleus deep brain stimulation (STN-DBS) have been described in patients with predominantly left-sided motor symptoms. The objective of this study was to evaluate if the body side of motor symptoms onset may predict motor outcome of bilateral STN-DBS.
Methods UNASSIGNED
This retrospective study included all consecutive PD patients treated with bilateral STN-DBS at Grenoble University Hospital from 1993 to 2015. Demographic, clinical and neuroimaging data were collected before (baseline condition) and 1 year after surgery (follow-up condition). The predictive factors of motor outcome at one-year follow-up, measured by the percentage change in the MDS-UPDRS-III score, were evaluated through univariate and multivariate linear regression analysis.
Results UNASSIGNED
A total of 233 patients were included with one-year follow-up after surgery [143 males (61.40%); 121 (51.90 %) right body onset; 112 (48.10%) left body onset; mean age at surgery, 55.31 ± 8.44 years; mean disease duration, 11.61 ± 3.87]. Multivariate linear regression analysis showed that the left side of motor symptoms onset did not predict motor outcome (β = 0.093, 95% CI = -1.967 to 11.497, p = 0.164).
Conclusions UNASSIGNED
In this retrospective study, the body side of motor symptoms onset did not significantly influence the one-year motor outcome in a large cohort of PD patients treated with bilateral STN-DBS.

Identifiants

pubmed: 35799771
doi: 10.3389/fnhum.2022.931858
pmc: PMC9253299
doi:

Types de publication

Journal Article

Langues

eng

Pagination

931858

Informations de copyright

Copyright © 2022 Bove, Cavallieri, Castrioto, Meoni, Schmitt, Bichon, Lhommée, Pélissier, Kistner, Chevrier, Seigneuret, Chabardès, Valzania, Fraix and Moro.

Déclaration de conflit d'intérêts

FC received personal fees from Zambon outside the submitted work. AC received research grants from France Parkinson Association and Medtronic. SM has received grant support from Medtronic. SC received grants and personal fees from Medtronic and Boston Scientific. VF received honoraria from AbbVie and Medtronic for consulting services and lecturing. EM has received honoraria from Abbott, Medtronic, Kyowa and Newronika for consulting and lecturing and received an educational grant from Boston Scientific. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Neurology. 2020 Jul 28;95(4):e384-e392
pubmed: 32611633
Mov Disord. 2010 Nov 15;25(15):2649-53
pubmed: 21069833
Neurology. 2021 Jun 2;:
pubmed: 34078713
Neurology. 1967 May;17(5):427-42
pubmed: 6067254
NPJ Parkinsons Dis. 2017 Jan 12;3:16024
pubmed: 28725706
Front Neurol. 2021 May 31;12:663232
pubmed: 34135850
J Neurol Neurosurg Psychiatry. 1995 Feb;58(2):174-9
pubmed: 7876847
Front Neurol. 2021 Jul 27;12:711045
pubmed: 34385975
Mov Disord. 2015 Dec;30(14):1921-5
pubmed: 26408124
Mov Disord. 2008 Nov 15;23(15):2129-70
pubmed: 19025984
N Engl J Med. 1998 Oct 15;339(16):1105-11
pubmed: 9770557
Sci Rep. 2022 Feb 22;12(1):3007
pubmed: 35194127
Mov Disord. 2021 Oct;36(10):2303-2313
pubmed: 34124799
Lancet. 1995 Jan 14;345(8942):91-5
pubmed: 7815888
J Parkinsons Dis. 2020;10(4):1611-1620
pubmed: 32741839
Mov Disord. 1999 Jul;14(4):572-84
pubmed: 10435493
Mov Disord. 1992;7(1):2-13
pubmed: 1557062
Ann Neurol. 2021 Mar;89(3):587-597
pubmed: 33349939
Arch Clin Neuropsychol. 1997;12(3):269-75
pubmed: 14588419
Mov Disord. 2013 May;28(5):668-70
pubmed: 23408503

Auteurs

Francesco Bove (F)

Neurology Unit, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

Francesco Cavallieri (F)

Neurology Unit, Department of Neuromotor and Rehabilitation, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Anna Castrioto (A)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Sara Meoni (S)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Emmanuelle Schmitt (E)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Amélie Bichon (A)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Eugénie Lhommée (E)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Pierre Pélissier (P)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Andrea Kistner (A)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Eric Chevrier (E)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Eric Seigneuret (E)

Division of Neurosurgery, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Stephan Chabardès (S)

Division of Neurosurgery, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Franco Valzania (F)

Neurology Unit, Department of Neuromotor and Rehabilitation, Azienda USL-IRCCS di Reggio Emilia, Reggio Emilia, Italy.

Valerie Fraix (V)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Elena Moro (E)

Division of Neurology, Grenoble Institute of Neurosciences, Inserm U1216, CHU of Grenoble, Grenoble Alpes University, Grenoble, France.

Classifications MeSH